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A COL4A3 gene mutation and post-transplant anti-a3(1V) collagen
alloantibodies in Alport syndrome. The X-linked Alport syndrome is
associated with mutations and deletions in COL.4A5 gene, one of six genes
which constitute the a-chains of type IV collagen in basement membranes.
The autosomal recessive form of Alport syndrome is characterized by
mutations and deletions in the COL4A3 and COL4A4 genes. A fraction of
Alport patients who undergo renal transplantation develop anti-glomeru-
lar basement membrane (GBM) nephritis, which results in loss of the
renal allograft function. Recently, the target for alloantibodies from an
X-linked Alport patient with complete COL4A5 gene deletion was
determined to be the a3 chain of type IV collagen. The present study
characterized the post-transplant alloantibodies from an autosomal reces-
sive Alport patient with anti-GBM glomerulonephritis and a COL4A3
gene mutation which predicted a loss of 85% of the a3(IV) NC1 domain.
The specificity of these new antibodies were studied using glomerular
basement membrane constituents and recombinant type IV collagen
domains. The results establish the target for the alloantibodies from an
autosomal recessive Alport patient with COL4A3 deletion as principally
the a3(IV) collagen chain, similar to the post-transplant alloantibodies
from X-linked Alport patients with COL4A5 gene deletions. The absence
of a3(IV) chain in the GBM of patients with both these forms of Alport
syndrome, due either to a failure of synthesis or a failure of assembly,
presumably leads to a loss of immunologic tolerance for the a3(IV) NC1
domain in transplanted allografts.
Alport syndrome is a progressive hereditary kidney disease
characterized by hematuria, sensorineural hearing loss, and ocular
lesions with structural defects in GBM [1—3]. The disease is
primarily X chromosome-linked, but autosomal forms of inheri-
tance are also known [4]. The X-linked syndrome is associated
with mutations and deletions in COL4A5 gene, which encodes the
a5(IV) chain, one of six genetically distinct type IV collagen gene
products [3, 5—7]. The rare autosomal forms of Alport syndrome
are associated with recessive mutations in the COL4A3 and
COL4A4 genes which encode the a3(IV) and a4(IV) chains,
respectively [8, 9].
Anti-GBM disease appears in 5 to 10% of Alport patients who
receive a kidney transplant following the development of renal
failure. In the recent years, insight into the structural nature of the
defect in Alport GBM has been determined by establishing the
target of anti-GBM alloantibodies produced by these patients
[10—14]. Alloantibodies from seven post-transplant Alport pa-
tients, for example, were found reactive to the NC1 domain of
type IV collagen [9—14]. Three of these antisera, under closer
scrutiny, did not bind to Alport GBM and were found reactive to
the a3(IV) chain [11]. Recently, post-transplant anti-GBM alloan-
tibodies harvested from a X-linked Alport patient with complete
COL4A5 gene deletion was characterized [15]. These alloantibod-
ies were also specifically targeted to the a3(IV) chain [15]. This
study suggested a pivotal role for the a5(IV) chain in the secretion
or assembly of type IV collagen co-expressing the a3(IV) moiety.
The present study characterizes the target antigen for the
post-transplant alloantibodies from an autosomal recessive Alport
patient with COL4A3 gene deletion.
Methods
Patient histoty
The case history of family VB is described elsewhere [8, 9]. The
affected female had hematuria from age 4, and typical ultrastruc-
tural lesions of Alport syndrome ott electron microscopy of a renal
biopsy and sensorineural deafness. Renal function deteriorated
gradually until hemodialysis was started at age 9. She received a
renal allograft at age 10 and developed anti-GBM nephritis six
months later. Her brother has hematuria, deafness, and deterio-
rating renal function. The parents have no hematuria, proteinuria
or deafness. There is no known consanguinity, but the parents and
their known ancestors originate from the same small village in the
Netherlands. The affected female in family VB has a deletion of
last 198 amino acids of the a3(IV) chain. This was predicted to
result in a chain termination after 33 amino acids of the NC1
domain.
GBM antigens and analytic assays
The preparation of the GBM constituents, fibronectin, laminin,
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heparan sulfate proteoglycan, entactin, 7 S domain of type IV
collagen, pepsin solubilized triple helical fragments of type IV
collagen and NC1 domains of type IV collagen a-chains was
described previously [16]. Recombinant human type IV collagen
a-chains (al-a5) were expressed in E. coli and purified as before
[17].
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Fig. 1. Immunofluoresence localization of the
alloantibody in renal tissues. The alloantibody
was analyzed for its capacity to bind Alport
GBM and transplant kidney. The alloantibodies
did not bind to Alport GBM (A). The
alloantibodies bind very strongly to the GBM of
the transplanted kidney, exhibiting the
characteristic linear staining (B). Some binding
was also observed to the TBM. The antibody
dilution used was 1:50.
SDS-PAGE in one and two dimensions was carried out with 10
to 20% linear gradient gels and the discontinuous buffer system of
Laemmli [18]. Electrophoresis in the first dimension of the
two-dimensional electrophoresis was performed according to
Langeveld et al [19] Electrophoresis in the second dimension was
pcrformed according to Timoneda et a! [20].
Immunofluoresence [11], Western blotting [16, 211, and direct
enzyme-linked immunosorbent assays (ELISA) were performed
as previously described for this laboratory [22]. Inhibition ELISA
was performed as previously described [231. The dilutions for the
a-chain specific antibodies were 1:50, a saturating antibody con-
centration for the binding of the bovine NCI hexamer. The
anti-al(IV) to a5(IV) chain specific antibodies have been previ-
ously described [16]. The a6(IV) chain specific antibody was made
recently to a conserved 12 amino acid peptide of the NC1 domain.
(R. Kalluri, J. Zhou, and B.G. Hudson, unpublished data).
Results
Localization of anti-GBM alloantibodies in renal tissues
Circulating post-transplant anti-GBM alloantibodies from the
Alport patient was evaluated for its capacity to bind the GBM of
the Alport kidney of the same patient by indirect immunofluores-
ence. The aildantibodies did not bind to the Alport GBM,
suggesting a lack of the certain GBM antigen(s) which are
otherwise present in the transplanted kidney (Fig. 1A). The
transplanted kidney showed endogenous IgG binding to the GBM
and TBM, and the alloantibody binding was further enhanced
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(Di-dimers) and a3, a4, a5 and a6 NC1 dimers (D2-dimers). At
the NC1 hexamer level, the alloantibodies bound strongly to the
54 kDa dimers, a 28 kDa monomer, and very faintly to a 26 kDa
monomer (data not shown), as visualized by one dimensional
immunoblotting. To further evaluate this binding in terms of type
IV collagen a-chains, we performed two-dimensional gel electro-
phoresis and immunoblotting using bovine NC1 hexamer. The
bovine NCI hexamer was used since all the spots originating from
the six a-chains have been identified based on their p1 and
molecular weight by two-dimensional gel electrophoresis (Identi-
fication of al-aS spots was previously reported by Gunwar et al
[16]. The monomeric and dimeric spots originating from the
a6(IV) was recently identified. R. Kalluri, J. Zhou, and B.G.
Hudson, unpublished data.) The alloantibodies reacted specifi-
cally to the a3(IV) NC1 dimers and monomers, identical to the
spots that bind to anti-a3(IV) chain specific antibodies as previ-
ously described [16] (Fig. 3). No reactivity was found with the
al(IV), a2(IV), a4(IV), a5(IV) and a6(IV) NC1 dimers and
monomers. Additionally, the alloantibodies did not react to the al
+ a2(IV) NC1 dimers and monomers, as evaluated by one
dimensional immunoblotting (data not shown). These results
establish the target for the alloantibodies as the a3(IV) chain of
bovine type IV collagen.
Inhibition ELISA
Fig. 2. Identification GBM constituent(s) that bind to the Alport alloanti-
bodies. The various GBM constituents were F, fibronectin, L, laminin,
HSP, heparan sulfate proteoglycan, E, entactin, 7 S, 7 S domain of type IV
collagen, pepsin solubilized TH, triple helical fragments of type IV
collagen and dimers and monomers of NC! domains of type IV collgen
a-chains. The dilution of alloantihodies was 1:500. The control serum did
not bind to any of the GBM constituents.
upon incubation with the circulating alloantibodies (Fig. 1B).
These results suggest that additional binding sites for the alloan-
tisera in the transplanted kidney are accessible in vitro compared
to in vivo, and that there is a structural difference within the GBM
of the Alport and transplanted kidney.
Specificity of alloantibodies to GBM constituents and bovine type
IV collagen domains
The specificity of post-transplant anti-GBM alloantibodies from
an autosomal recessive Alport patient with COL4A3 deletion was
determined using bovine GBM constituents and bovine NC1
domains of the a-chains of type IV collagen. The GBM constit-
uents used were: fibronectin, laminin, heparan sulfate proteogly-
can and entactin. Bovine type IV collagen domains used were: 7 S
domain of type IV collagen, pepsin solubilized triple helical
fragments of type IV collagen and dimeric and monomeric NC1
domains of type IV collagen a-chains. The alloantibodies reacted
specifically to the a3(IV) NC1 containing dimers and a3(IV) NC1
monomers (Fig. 2).
Specificity of the alloantibodies to bovine type IV collagen NC1
domains by one- and two-dimensional gel electrophoresis
and immunoblotting
The alloantibodies from the affected patient were analyzed by
one- and two-dimensional gel electrophoresis and immunoblot-
ting with the bovine NC1 hexamer, bovine al + a2 NC1 dimers
Type IV collagen a-chain specific antibodies were used to
perform inhibition ELISA using bovine NC1 hexamer as the
antigen. The NC1 hexamer was allowed to bind with one of the six
a-chain specific antibodies and subsequently followed with the
Alport alloantibodies. The anti-a3(IV) chain specific antibodies
inhibited the alloantibodies binding (Figs. 4 A and B). All the
other antibodies did not inhibit the alloantibodies binding to the
NC1 hexamer. These results establish the alloantibodies as anti-
a3(IV)NC1 antibodies.
Specificity of the alloantibodies to the recombinant human type IV
collagen NC1 domains
The alloantibodies were further analyzed for their capacity to
bind recombinant human type IV collagen NC1 domains (al to
a5). The alloantibodies reacted very strongly to the recombinant
a3(IV) NC1 (Fig. 5) and to a very minor degree with the
recombinant a5(IV)NC1 domain (1:200 dilution of alloantisera,
lost at 1:500). The weak reactivity with the a5(IV)NC1 may be a
cross-reactivity phenomenon, due to the high homology between
the NC1 domains [24]. Alternatively, the weak binding may be
specific reactivity only observed with human a5(IV)NC1 se-
quence; repeating the gel with half the amount of target NC1
domains eliminated evidence of weak binding while preserving the
strong reactivity to a3. These results establish the principal target
for post-transplant anti-GBM nephritis in an Alport patient with
COL4A3 gene deletion as the a3 chain of type IV collagen.
Discussion
In several previous studies, the target for X-linked Alport
alloantibodies was identified as the NC1 domain of type IV
collagen [10—14]. Hudson et al have shown the target for three
post-transplant alloantibodies as the a3(IV) chain [11]. Kleppel et
al implicated the a5(IV) chain as a target for alloantibodies in
their patients [25, 26]. Their assumption of a5 chain reactivity was
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Fig. 3. Identification of the bovine NC] domains
that bind the Alport alloantibodies. Bovine NC1
hexamer was prepared as previously described
[16]. The two dimensional electrophorcsis and
immunoblotting was used to analyze the
binding NC1 hexamer with Alport
alloantibodies. The spots that reacted with the
alloantibodies are 16, 17, 18, 20, 22 and 23. All
these spots have been previously identified by
chain specific antibodies and N-terminal amino
acid sequencing (identical spots analyzed from
the a3(IV)NC1 dimer pool) as the a3(IV)
dimers and monomers [16]. The dimers and
monomers of NCI domain are shown as D and
M, respectively. The molecular weight of dimers
(D) and monomers (M) was around 54 kDa
and 28 kDa, respectively. The p1 range (6 to 8)
is shown at the bottom. This figure can be
compared with the reactive spots seen in the
Fig. 3, panels F, G and H in the manuscript by
Gunwar et al [161.
based on two lines of evidence: the alloantihodies reacted to a 26
kDa band in the immunoblotting studies with NC1 hexamer [25],
and a monoclonal antibody which binds a 26 kDa band in NC1
hexamer [25] and also binds to the human recombinant a5(IV)
NCI domain [27]. Although these studies implicate a3(IV) and
a5(IV) chain as the target for X-linked Alport alloantibodies, the
nature of mutation(s) leading to a particular genetic defect in
these patients was not available. Since our previous study with
alloantibodies from an X-linked Alport patient with COL4A5
gene deletion revealed anti-cs3(IV) antibodies [15], we addressed
the specificity of Alport alloantibodies from an autosomal reces-
sive Alport patient with COL4A3 gene deletion.
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Fig. 4. Inhibition ELISA with type JJ/ collagen a-chain specific antibodies. A. A dilution curve of Alport alloantibodies binding to the NC1 hexamer as
analyzed by direct ELISA. B. The plates were coated with 200 ng of NC1 hexamer after boiling for 10 minutes in the presence of 6 M guanidine HCI,
50 mM tris-Cl pH 7.5. The NC1 hexamer was allowed to bind to one of the six different a-chain specific antibodies [(0) al + a2; (•) a3; (•) a4; ()
a5; (A) a6], upon which the NC1 hexamer was allowed to bind with Alport alloantibodies. The binding of the Alport alloantibodies was significantly
inhibited by anti-a3(IV) antibodies.
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Fig. 5. Identification of recombinant human NCI domain(s) that bind
A/port alloantibodies. The recombinant NC1-fusion proteins (al to s5)
were resolved by SDS-PAGE and immunoblotted with Alport alloanti-
bodies. The alloantibodies reacted primarily to the a3(IV)NC1 domain.
Some weak binding to the a5(IV) NC1 domain is also observed.
The present study identifies the principal target for the circu-
lating alloantibodies as the a3(IV) chain of type IV collagen.
However, anti-a5(IV) antibodies cannot be completely ruled out
because some veiy weak binding was observed with the human
recombinant a5(IV) NC1 domain. The results from this study,
however, establish for the first time the absence of 85% cs3(IV)
NCI domain in an autosomal recessive Alport patient and, in the
same patient, the production of an alloantibody targeted to
a3(IV) chain. This finding suggests that anti-cs3(IV) alloantibod-
ies can mediate the anti-GBM nephritis and loss of allograft
function in patients with this hereditary defect following trans-
plantation, similar to an X-linked Alport patient with complete
COL4A5 gene deletion [15].
a5(IV) and a3(IV) collagen chains are co-expressed in normal
basement membrane [16]. When a5(IV) or a3(IV) NCI domains
are mutated in patients with Alport syndrome, who later receive
kidney allografts for renal failure, it is somewhat curious why
alloantibodies only principally appear reactive to the cs3(IV)
chain. Antibodies to the a3(IV) NC1 domain are not present in
the normal population because the minimal condition required
for the appearance of tissue-specific immune response is a loss or
failure to acquire immunologic tolerance to self [28]. The possible
explanations for a predominance of tissue-specific a3(IV) al-
loantibodies in post-transplantation Alport syndrome include: (1)
an expected loss of immunologic tolerance to both a3(IV)
and 5(IV) chains in Alport-affected individuals, since a3 and
cs5 chains tend to be expressed together [16], but a lack of im-
mune response genes for a5(IV) or preferred immune response
genes for a3(IV) in most affected individuals favoring an
a3(IV) responder phenotype; or (2) an expected loss of immuno-
logic tolerance to both a3(IV) and a5(IV) chains in Alport-
affected individuals who have appropriate immune response genes
for a5(IV) and cs3(IV) chains, but a different level of exposure
to cs3(IV) and a5(IV) chains in normal kidney. In this instance,
a3(IV) homotrimers would so predominate in normal kidney (in
this case the transplant) compared to the a5(IV) chain [161, that
a5(IV) species would be relatively invisible to the immune system,
or alternatively, the assembly of the cw5(IV) chain in normal
kidney basement membrane would create a non-immunogenic or
privileged site. Any or all of these possibilities could explain the
serologic reactions observed to date. The relative invisibility, or
privilege of non-recognition of a5(IV) in most normal basement
membrane combined with a high responder polymorphism to-
wards the a3(IV) NC1 domain in occasional individuals, as a
hypothesis, best explains what has been observed in post-trans-
plant Alport syndrome when tolerance to some species of type IV
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